跳至主要内容
临床试验/NCT00002284
NCT00002284已完成不适用

A Pilot Study To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients Receiving a Bone Marrow Transplant

Glaxo Wellcome2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
试验地点
2

研究概览

简要总结

To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III activity and drug levels.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
12 Years 至 50 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.
  • Concurrent Medication:
  • Other anti-retroviral agents.
  • Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded.
  • Patients must be:
  • HTLV III antibody positive by ELISA or Western blot or HTLV III viremia.
  • At high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC).
  • Also patient must fall into one of the following categories:
  • Have an HIV seronegative identical twin to serve as a bone marrow donor.
  • Have documentation of large cell/diffuse histiocytic lymphoma/DPDL.
  • Be a good risk candidate for bone marrow transplant.

排除标准

  • 未提供

研究者

发起方
Glaxo Wellcome
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验